Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Parmiani

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Cancers|March 16, 2016
Melanoma Cancer Stem Cells: Markers and FunctionsGiorgio Parmiani
Oncoimmunology|November 20, 2012
The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn's hypothesis in the human melanoma systemGiorgio Parmiani, Cristina Maccalli
Cytotechnology|November 13, 2008
Limitations of the cancer stem cell theoryLuca Vezzoni, Giorgio Parmiani
Recent Patents on Biotechnology|June 29, 2011
Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumorsSeyed Amir Jalali, Giorgio Parmiani
Cancer Immunology, Immunotherapy : CII|August 17, 2004
A listing of human tumor antigens recognized by T cells: March 2004 updateLuisa Novellino, Chiara Castelli, Giorgio Parmiani
Cancer Immunology, Immunotherapy : CII|December 18, 2008
TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumorsCristina Maccalli, Samantha Scaramuzza, Giorgio Parmiani
Immunological Investigations|March 14, 2017
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of ImmunotherapyCristina Maccalli, Giorgio Parmiani, Soldano Ferrone
Melanoma Research|August 12, 2004
What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003Maria Rescigno, Alessandro Testori, Giorgio Parmiani
Vaccines|September 8, 2015
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyGiorgio Parmiani, Cristina Maccalli, Michele Maio
Tumori|June 21, 2008
The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European levelMichele Maio, Ester Fonsatti, Arianna Burigo, et al.
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Cancers|March 16, 2016
Melanoma Cancer Stem Cells: Markers and FunctionsGiorgio Parmiani
Oncoimmunology|November 20, 2012
The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn's hypothesis in the human melanoma systemGiorgio Parmiani, Cristina Maccalli
Cytotechnology|November 13, 2008
Limitations of the cancer stem cell theoryLuca Vezzoni, Giorgio Parmiani
Recent Patents on Biotechnology|June 29, 2011
Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumorsSeyed Amir Jalali, Giorgio Parmiani
Cancer Immunology, Immunotherapy : CII|August 17, 2004
A listing of human tumor antigens recognized by T cells: March 2004 updateLuisa Novellino, Chiara Castelli, Giorgio Parmiani
Cancer Immunology, Immunotherapy : CII|December 18, 2008
TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumorsCristina Maccalli, Samantha Scaramuzza, Giorgio Parmiani
Immunological Investigations|March 14, 2017
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of ImmunotherapyCristina Maccalli, Giorgio Parmiani, Soldano Ferrone
Melanoma Research|August 12, 2004
What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003Maria Rescigno, Alessandro Testori, Giorgio Parmiani
Vaccines|September 8, 2015
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyGiorgio Parmiani, Cristina Maccalli, Michele Maio
Tumori|June 21, 2008
The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European levelMichele Maio, Ester Fonsatti, Arianna Burigo, et al.
Pageof 11